A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications. | LitMetric

AI Article Synopsis

  • Telmisartan is an effective antihypertensive medication for managing blood pressure in patients with Stage I hypertension, particularly those with type 2 diabetes.
  • The study compared the effects of telmisartan on blood pressure and glucose levels in patients with diabetes but no complications (Group A) and those with complications (Group B).
  • Both groups saw significant reductions in systolic and diastolic blood pressure, with some improvements in glucose levels, indicating telmisartan's efficacy regardless of diabetes complications.

Article Abstract

Introduction: Telmisartan is one of the preferred choices of antihypertensive in patients of diabetes with hypertension (HTN) and lowers blood pressure (BP) effectively.

Objective: The objective of the study was to determine BP-lowering efficacy of telmisartan monotherapy in patients of Stage I HTN with or without complications of type 2 diabetes mellitus (T2DM).

Materials And Methods: In this retrospective study, patients of T2DM without (Group A) or with (Group B) complications who had Stage I HTN and were prescribed telmisartan (20-80 mg/day) treatment were identified from database. Patients included were adults 18 years and above with BP ≥140/80 mmHg but <160/100 mmHg. Data related to demographics, systolic and diastolic BP, blood glucose parameters, and weight before initiation of telmisartan and at the end of 12 weeks treatment were compared with appropriate statistics.

Results: In 132 patients included, 28 (21.2%) patients had one or more complications of T2DM. Mean age in Group A and B was similar whereas mean duration of diabetes was significantly higher in Group B than Group A (10.0 ± 5.8 vs. 7.1 ± 5.9, = 0.023). Telmisartan 40 mg was most frequently used strength (97.1% and 100.0% patients in two groups). Change from baseline in systolic BP in Groups A and B was -19.5 mmHg (95% confidence interval [CI] -16.3, -22.7; < 0.0001) and -24.9 mmHg (95% CI -17.3, -32.5; < 0.0001), respectively. Reduction in diastolic BP was also significant in two groups. There were no significant differences in adjusted means of systolic and diastolic BP in two groups. In Group A and B, change from baseline in fasting glucose was -3.7 mg/dL ( = 0.647) and -8.4 mg/dL ( = 0.593); in postmeal glucose was -14.8 mg/dL ( = 0.280) and -36.9 mg/dL ( = 0.046), respectively.

Conclusion: Telmisartan is effective in lowering BP and improving metabolic parameters in patients of T2DM with or without complications. A larger and long duration study is needed to substantiate our findings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176690PMC
http://dx.doi.org/10.4103/picr.PICR_93_17DOI Listing

Publication Analysis

Top Keywords

blood pressure
8
type diabetes
8
stage htn
8
patients
5
telmisartan
4
telmisartan blood
4
pressure patients
4
patients type
4
diabetes complications
4
complications introduction
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!